Susquehanna International Group
MRNA icon

Susquehanna International Group’s Moderna MRNA Stock Holding History

Susquehanna International Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279M Sell
5,487,300
-52,500
-0.9% -$2.45M 0.03% 409
2025
Q4 		$163M Sell
5,539,800
-1,553,700
-22% -$42.2M 0.02% 622
2025
Q3 		$183M Buy
7,093,500
+784,100
+12% +$21.9M 0.02% 576
2025
Q2 		$174M Buy
6,309,400
+1,232,900
+24% +$32.5M 0.02% 500
2025
Q1 		$144M Sell
5,076,500
-596,100
-11% -$21.2M 0.02% 503
2024
Q4 		$236M Buy
5,672,600
+1,864,800
+49% +$89.1M 0.04% 371
2024
Q3 		$254M Buy
3,807,800
+1,175,400
+45% +$108M 0.04% 328
2024
Q2 		$313M Buy
2,632,400
+672,400
+34% +$85.1M 0.06% 248
2024
Q1 		$209M Sell
1,960,000
-339,000
-15% -$34.2M 0.04% 392
2023
Q4 		$229M Sell
2,299,000
-187,400
-8% -$15.8M 0.04% 344
2023
Q3 		$257M Sell
2,486,400
-46,000
-2% -$5.13M 0.05% 276
2023
Q2 		$308M Buy
2,532,400
+173,000
+7% +$23.1M 0.06% 236
2023
Q1 		$362M Sell
2,359,400
-488,500
-17% -$80.6M 0.08% 202
2022
Q4 		$512M Buy
2,847,900
+535,900
+23% +$87.6M 0.13% 114
2022
Q3 		$273M Sell
2,312,000
-12,300
-0.5% -$1.87M 0.07% 212
2022
Q2 		$332M Sell
2,324,300
-1,564,200
-40% -$224M 0.08% 179
2022
Q1 		$670M Sell
3,888,500
-1,225,800
-24% -$206M 0.12% 122
2021
Q4 		$1.3B Sell
5,114,300
-1,367,500
-21% -$400M 0.19% 72
2021
Q3 		$2.49B Buy
6,481,800
+1,980,700
+44% +$730M 0.33% 36
2021
Q2 		$1.06B Sell
4,501,100
-1,355,000
-23% -$242M 0.15% 96
2021
Q1 		$767M Buy
5,856,100
+673,200
+13% +$97.6M 0.12% 128
2020
Q4 		$541M Buy
5,182,900
+2,526,300
+95% +$256M 0.09% 173
2020
Q3 		$188M Buy
2,656,600
+813,800
+44% +$56.7M 0.04% 356
2020
Q2 		$118M Buy
1,842,800
+1,061,100
+136% +$58.1M 0.03% 450
2020
Q1 		$23.4M Buy
781,700
+560,000
+253% +$12.9M 0.01% 1081
2019
Q4 		$4.34M Sell
221,700
-22,500
-9% -$399K ﹤0.01% 3179
2019
Q3 		$3.89M Buy
244,200
+18,700
+8% +$276K ﹤0.01% 3088
2019
Q2 		$3.3M Buy
225,500
+88,700
+65% +$1.91M ﹤0.01% 3301
2019
Q1 		$2.78M Buy
+136,800
New +$2.54M ﹤0.01% 3242

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's MRNA Position: Q1 2026 in Review

Susquehanna International Group reduced its Moderna (MRNA) stake by 97% in Q1 2026, selling an estimated $72.8M and leaving 54,840 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #5422.

Susquehanna International Group first reported a position in MRNA in Q4 2018 and has held it in 28 quarters since. The position peaked at $270M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Susquehanna International Group held 54,840 shares of Moderna worth $2.79M as of Q1 2026.
  • Susquehanna International Group sold 1,560,559 Moderna shares in Q1 2026, an estimated $72.8M.
  • Moderna made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5422 holding.
  • Susquehanna International Group first reported a position in Moderna in Q4 2018 and has held it in 28 quarters since.
  • Susquehanna International Group's Moderna position peaked at $270M in Q3 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.